Aventis Ketek
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Data from ten pivotal Phase III trials of telithromycin were presented at the 40th annual Interscience Conference on Antimicrobial Agents and Chemotherapy in Toronto. The trials showed that Ketek had comparable efficacy to comparator antibiotics against community-acquired pneumonia (CAP), acute exacerbation of chronic bronchitis, sinusitis, and phyarygitis/tonsillitis. Aventis submitted an NDA in March for a once-daily dosing regimen for CAP, AECB and acute sinusitis in adults, for pharyngitis/tonsillitis in patients 13 and up and a short-course treatment regimen in all indications except CA
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.